The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

The next round of Medicare's historic drug price negotiations could save billions for seniors taking medications like Ozempic ...

Donna Cooper holds up a dosage of Wegovy, a drug used for weight loss, at her home in Front Royal, Va., on Friday, March 1, 2024. (AP Photo/Amanda Andrade-Rhoades, File) Dr. Mehmet Oz, President ...

Administration officials reversed a decision made during the Biden presidency that would have given millions of people access to weight-loss drugs paid for Medicare and Medicaid. By Margot Sanger ...

Trump proposed a change to Medicare price talks that has long been sought after by the pharmaceutical industry.

The Centers for Medicare & Medicaid Services said on Friday it did not move forward with a proposal put forth by the Biden administration for Medicare coverage of weight-loss drugs such as Novo ...

The drugs were first used to treat diabetes but drugmakers have introduced newer brands such as Wegovy and Zepbound approved for people with obesity. Medicare currently covers GLP-1 drugs such as ...

on Wednesday called on the Trump administration to back a Biden-era rule that would expand access to GLP-1 medications, such as Ozempic and Wegovy, for millions of Medicare and Medicaid beneficiaries.

As discussions unfold, Kennedy seeks to balance drug accessibility with concerns about the long-term costs of providing GLP-1 ...

The rule was not expected to be finalized until Trump took office. Medicare does pay for drugs like Wegovy for patients who have heart disease and need to reduce their risk of future heart attacks ...